Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab in ARID1A-Mutated Esophageal and Gastric Adenocarcinomas
NCT06824363Phase 1Recruiting
- Sponsor
- University of California, Irvine
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tremelimumab and durvalumab in esophageal adenocarcinoma (EAC) and gastric adenocarcinoma, sponsored by University of California, Irvine. Primary endpoints: Percentage of Subjects Completing Study Treatment at 2 years and Percentage of Subjects Completing Post-Treatment Biopsy at 2 years. Started May 2026; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06824363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824363.